Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Comparison of potency assays to assess SARS-CoV-2 neutralizing antibody capacity in COVID-19 convalescent plasma
Christine von Rhein, Tatjana Scholz, Lisa Henß, et al.
Journal of Virological Methods (2020) Vol. 288, pp. 114031-114031
Open Access | Times Cited: 90

Showing 1-25 of 90 citing articles:

Immunogenicity and efficacy of heterologous ChAdOx1–BNT162b2 vaccination
Bruno Pozzetto, Vincent Legros, Sophia Djebali, et al.
Nature (2021) Vol. 600, Iss. 7890, pp. 701-706
Open Access | Times Cited: 199
Anti-Spike Protein Assays to Determine SARS-CoV-2 Antibody Levels: a Head-to-Head Comparison of Five Quantitative Assays
Thomas Perkmann, Nicole Perkmann‐Nagele, Thomas Köller, et al.
Microbiology Spectrum (2021) Vol. 9, Iss. 1
Open Access | Times Cited: 177
SARS-CoV-2 RNAemia and proteomic trajectories inform prognostication in COVID-19 patients admitted to intensive care
Clemens Gutmann, Kaloyan Takov, Sean A. Burnap, et al.
Nature Communications (2021) Vol. 12, Iss. 1
Open Access | Times Cited: 146
The Main Molecular and Serological Methods for Diagnosing COVID-19: An Overview Based on the Literature
Bruna Aparecida Souza Machado, Katharine Valéria Saraiva Hodel, Valdir Barbosa-Júnior, et al.
Viruses (2020) Vol. 13, Iss. 1, pp. 40-40
Open Access | Times Cited: 70
Disease Severity, Fever, Age, and Sex Correlate With SARS-CoV-2 Neutralizing Antibody Responses
Stephan Schlickeiser, Tatjana Schwarz, Sophie Steiner, et al.
Frontiers in Immunology (2021) Vol. 11
Open Access | Times Cited: 64
Immunogenicity of an inactivated SARS-CoV-2 vaccine in people living with HIV-1: a non-randomized cohort study
Yanmeng Feng, Yifan Zhang, Zhangyufan He, et al.
EClinicalMedicine (2021) Vol. 43, pp. 101226-101226
Open Access | Times Cited: 61
Immunogenicity of COVID-19 Tozinameran Vaccination in Patients on Chronic Dialysis
Eva Schrezenmeier, Léon Bergfeld, David Hillus, et al.
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 59
Evaluation of a commercial ELISA as alternative to plaque reduction neutralization test to detect neutralizing antibodies against SARS-CoV-2
Natalie Hofmann, Marica Grossegesse, Markus Neumann, et al.
Scientific Reports (2022) Vol. 12, Iss. 1
Open Access | Times Cited: 39
Diagnostics and analysis of SARS-CoV-2: current status, recent advances, challenges and perspectives
Tao Dong, Mingyang Wang, Junchong Liu, et al.
Chemical Science (2023) Vol. 14, Iss. 23, pp. 6149-6206
Open Access | Times Cited: 35
A comprehensive review on pharmacologic agents, immunotherapies and supportive therapeutics for COVID-19
Khan Sharun, Ruchi Tiwari, Mohd I. Yatoo, et al.
Narra J (2022) Vol. 2, Iss. 3, pp. e92-e92
Open Access | Times Cited: 34
Correlation between pseudotyped virus and authentic virus neutralisation assays, a systematic review and meta-analysis of the literature
Diego Cantoni, Craig Wilkie, Emma M. Bentley, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 20
Comparative analysis of SARS-CoV-2 neutralization titers reveals consistency between human and animal model serum and across assays
Barbara Mühlemann, Samuel Wilks, Lauren Baracco, et al.
Science Translational Medicine (2024) Vol. 16, Iss. 747
Closed Access | Times Cited: 5
SARS-CoV-2 Neutralization Assays Used in Clinical Trials: A Narrative Review
Yeqing Sun, Weijin Huang, Hongyu Xiang, et al.
Vaccines (2024) Vol. 12, Iss. 5, pp. 554-554
Open Access | Times Cited: 5
Evaluation of a multi-species SARS-CoV-2 surrogate virus neutralization test
Carmen W. E. Embregts, Babs E. Verstrepen, Jan A. M. Langermans, et al.
One Health (2021) Vol. 13, pp. 100313-100313
Open Access | Times Cited: 37
Function Is More Reliable than Quantity to Follow Up the Humoral Response to the Receptor-Binding Domain of SARS-CoV-2-Spike Protein after Natural Infection or COVID-19 Vaccination
Carlos A. Sariol, Petraleigh Pantoja, Crisanta Serrano-Collazo, et al.
Viruses (2021) Vol. 13, Iss. 10, pp. 1972-1972
Open Access | Times Cited: 32
Humoral Immune Response in IBD Patients Three and Six Months after Vaccination with the SARS-CoV-2 mRNA Vaccines mRNA-1273 and BNT162b2
Richard Vollenberg, Phil‐Robin Tepasse, Joachim Kühn, et al.
Biomedicines (2022) Vol. 10, Iss. 1, pp. 171-171
Open Access | Times Cited: 23
The Serological Sciences Network (SeroNet) for COVID-19: Depth and Breadth of Serology Assays and Plans for Assay Harmonization
Amy B. Karger, James D. Brien, Jayne M. Christen, et al.
mSphere (2022) Vol. 7, Iss. 4
Open Access | Times Cited: 23
Cutting Edge: Serum but Not Mucosal Antibody Responses Are Associated with Pre-Existing SARS-CoV-2 Spike Cross-Reactive CD4+ T Cells following BNT162b2 Vaccination in the Elderly
Lil Meyer-Arndt, Tatjana Schwarz, Lucie Loyal, et al.
The Journal of Immunology (2022) Vol. 208, Iss. 5, pp. 1001-1005
Open Access | Times Cited: 22
Development of SARS-CoV-2 Specific IgG and Virus-Neutralizing Antibodies after Infection with Variants of Concern or Vaccination
Franziska Neumann, Ruben Rose, Janine Römpke, et al.
Vaccines (2021) Vol. 9, Iss. 7, pp. 700-700
Open Access | Times Cited: 31
Antigen-Specific CD4+ T-Cell Activation in Primary Antibody Deficiency After BNT162b2 mRNA COVID-19 Vaccination
Kai M. T. Sauerwein, Christoph B. Geier, R Stemberger, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 19
Review of therapeutic mechanisms and applications based on SARS-CoV-2 neutralizing antibodies
Mingtao Liu, Hui Gan, Zhiman Liang, et al.
Frontiers in Microbiology (2023) Vol. 14
Open Access | Times Cited: 12
Characterization of the SARS-CoV-2 Neutralization Potential of COVID-19–Convalescent Donors
Bernd Jahrsdörfer, Rüdiger Groß, Alina Seidel, et al.
The Journal of Immunology (2021) Vol. 206, Iss. 11, pp. 2614-2622
Open Access | Times Cited: 24
Donors for SARS-CoV-2 Convalescent Plasma for a Controlled Clinical Trial: Donor Characteristics, Content and Time Course of SARS-CoV-2 Neutralizing Antibodies
Sixten Körper, Bernd Jahrsdörfer, Victor M. Corman, et al.
Transfusion Medicine and Hemotherapy (2021) Vol. 48, Iss. 3, pp. 137-147
Open Access | Times Cited: 24
Evaluation of commercial Anti-SARS-CoV-2 neutralizing antibody assays in seropositive subjects
Kahina Saker, Bruno Pozzetto, Vanessa Escuret, et al.
Journal of Clinical Virology (2022) Vol. 152, pp. 105169-105169
Open Access | Times Cited: 17
Optimization and evaluation of a live virus SARS-CoV-2 neutralization assay
Anders Frische, Patrick Terrence Brooks, Mikkel Gybel‐Brask, et al.
PLoS ONE (2022) Vol. 17, Iss. 7, pp. e0272298-e0272298
Open Access | Times Cited: 17
Page 1 - Next Page

Scroll to top